Literature DB >> 10408255

Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels.

H Uneyama1, H Uchida, T Konda, R Yoshimoto, N Akaike.   

Abstract

The blocking effects of cilnidipine and other dihydropyridines on L-type cardiac Ca2+ channels (I(Ca,L)) and N-type sympathetic Ca2+ channel currents (I(Ca,N)) were studied using a whole-cell patch-clamp technique. At -80 mV, cilnidipine had little inhibitory effect below concentrations of 1 microM on I(Ca,L) (IC50 value; 17 microM). However, 1 microM cilnidipine strongly shifted the steady-state inactivation curve of I(Ca,L) toward negative potentials without changing the current-voltage relationship. Each action of cilnidipine was characterized by a high affinity for the inactivated channel in preference to the resting channel. The IC50 values of dihydropyridines for I(Ca,L) were in the range between 0.01 and 10 microM, and those for I(Ca,N) were between 3 and 30 microM. Cilnidipine had the strongest affinity for I(Ca,N) among the dihydropyridines tested. These results suggest that cilnidipine did not cause hypotension-evoked tachycardia deficiency by depression of cardiac L-type channels but by sympathetic N-type channels blockade.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408255     DOI: 10.1016/s0014-2999(99)00237-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  The fourth-generation Calcium channel blocker: cilnidipine.

Authors:  K Sarat Chandra; G Ramesh
Journal:  Indian Heart J       Date:  2013-12

2.  L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.

Authors:  Shizuka Aritomi; Tomoyuki Konda; Michihiro Yoshimura
Journal:  Heart Vessels       Date:  2011-10-12       Impact factor: 2.037

Review 3.  Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update.

Authors:  Alberto Milan; Mimma A Caserta; Eleonora Avenatti; Sara Abram; Franco Veglio
Journal:  Intern Emerg Med       Date:  2010-05-18       Impact factor: 3.397

4.  An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation.

Authors:  Kazuko Tajiri; Jean-Baptiste Guichard; Xiaoyan Qi; Feng Xiong; Patrice Naud; Jean-Claude Tardif; Antoine Da Costa; Kazutaka Aonuma; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

5.  Oral administration of cilnidipine to patients with hypertensive intracerebral hemorrhage in the acute stage: significance and role of an N-type calcium channel blocker.

Authors:  A Matsuno; F Ide; H Tanaka; S Asano; S Miyawaki; T Uno; J Tanaka; H Nakaguchi; M Sasaki; M Murakami; N Fuke
Journal:  Ir J Med Sci       Date:  2009-12       Impact factor: 1.568

6.  Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.

Authors:  Kai Nagasawa; Keiji Takahashi; Natsumi Matsuura; Miwa Takatsu; Takuya Hattori; Shogo Watanabe; Eri Harada; Kazumi Niinuma; Toyoaki Murohara; Kohzo Nagata
Journal:  Hypertens Res       Date:  2014-09-11       Impact factor: 3.872

7.  Cilnidipine and magnesium sulfate supplement ameliorates hyperglycemia, dyslipidemia and inhibits oxidative-stress in fructose-induced diabetic rats.

Authors:  Most Sumaiya Khatun Kali; Md Rafiqul Islam Khan; Ranjan Kumar Barman; Md Farhad Hossain; Mir Imam Ibne Wahed
Journal:  Heliyon       Date:  2021-12-26

8.  Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists.

Authors:  Keiichi Ikeda; Tsuyoshi Isaka; Kouki Fujioka; Yoshinobu Manome; Katsuyoshi Tojo
Journal:  Int J Endocrinol       Date:  2012-10-11       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.